Speech-Language Pathologists in Ionia, MI Accepting Medicare

4 Speech-Language Pathologists found. Showing 1 - 4

Mrs. Riley Mccormick Pawlanta, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 375 Apple Tree Dr, Ionia, MI 48846 Phone: 616-527-1790

Janean Kriss Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 375 Apple Tree Dr, Ionia, MI 48846 Phone: 616-527-1790

Mrs. Kendra Leann Horton, M.A., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 375 Apple Tree Dr # Mi48846, Ionia, MI 48846 Phone: 616-527-1790

Mrs. Dana Joelle Lepien, MS, CCC/SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 2905 Jefferson Rd, Ionia, MI 48846 Phone: 616-446-2264

News Archive

BWH, DFCI researchers receive $10 million to test effectiveness of aspirin in women with breast cancer

Researchers from Brigham and Women's Hospital and Dana-Farber Cancer Institute have received a $10 million Breakthrough Award from the Department of Defense's Office of the Congressionally Directed Medical Research Program to test whether aspirin helps women with breast cancer avoid recurrence and live longer.

LCA launches webpage with information on lung cancer meant for veterans

Lung Cancer Alliance (LCA) salutes all veterans today on Veterans Day and announces the launch of a new webpage with information specifically for veterans on lung cancer - the leading cause of cancer death among veterans.

Study shows how auditory perception and motor processes work together

How do people coordinate their actions with the sounds they hear? This basic ability, which allows people to cross the street safely while hearing oncoming traffic, dance to new music or perform team events such as rowing, has puzzled cognitive neuroscientists for years.

Acucela completes patient enrollment in Phase 2b/3 clinical trial of emixustat hydrochloride

Acucela Inc., a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases, today announced that it has completed enrollment in its ongoing Phase 2b/3 clinical trial investigating emixustat in subjects with geographic atrophy (GA) associated with dry age-related macular degeneration (AMD).

Read more Medical News

› Verified 2 days ago